$ABBV News

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $300

B of A Securities Maintains Buy on AbbVie, Raises Price Target to $276

RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $280

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $295

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $261

JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $280

SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY

AbbVie Earnings Preview: What to Expect

Is AbbVie (ABBV) Fully Valued After Its Tepkinly Approval?

EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma

3 Dividend Aristocrats to Buy in July

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

AbbVie’s TEPKINLY + R2 Becomes First Bispecific Therapy Approved In Europe For Relapsed Follicular Lymphoma Following Phase 3 Success

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $265

AbbVie (ABBV) Faces Congressional Probe Over China Clinical Trials